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patients per annum following colony stimulating factors, predom-
inantly GCSF /- chemotherapy. We observed that in 5 patients
after routine chemotherapy, PEG-ﬁligrastim mobilised sufﬁcient
numbers of CD34 cells for collection, with impressive CD34
counts both in the blood and in the ﬁnal CD34/kg collected.
This has led to a 2 year prospective observational study since July
2006 to investigate the numbers of CD34 cells in the blood of
children following administration of PEG-ﬁligrastim post chemo-
therapy. The aim is to determine the correlation between the
recovering white cell count (WCC) and increasing CD34 count.
This will guide the commencement of PBSC harvesting after the
use of PEG-ﬁligrastim to mobilise PBSC’s. All children in the
oncology unit who are already scheduled to receive PEG-ﬁlgrastim
are eligible. The dose of PEG-ﬁlgrastim is based on weight. It is
not administered to children <10kg.
Twelve patients have been enrolled on the study since its com-
mencement in July 2006.These patients received subcutaneous
PEG-ﬁligrastim following protocol driven chemotherapy. Five of
the twelve patients achieved a peripheral CD34 count of  20 
106/ml which is the minimum CD34 count required at CHW for
commencement of PBSC harvest. Three of the 12 patients did not
achieve a peripheral CD34 count  8  106/ml over a 20 day
period with increasingWCC, the average CD34 count being1
106/ml. Four patients are awaiting count recovery post chemother-
apy  PEG-ﬁligrastim at time of report.
Early results from this study indicate that PEG-ﬁligrastim may
be considered for patients requiring PBSC harvest in the paediatric
setting. The once only injection allows greater compliance with
paediatric patients.
Optimum timing remains a question which should be answered
with continued accrual of patient numbers into the study.
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Critical care nursing has a reputation of being both skillfully
demanding along with emotionally challenging. To ensure the
greatest quality of care to patients it is necessary to design orien-
tation programs for new nurses that prepare them for the chal-
lenges that will arise. Rapidly advancing technology, busy and
complex medication programs, and treatment modalities have re-
sulted in a tremendous demand for highly trained and well edu-
cated nursing staff. The prolonged nursing shortage has greatly
impacted the nursing work force. Historically highly specialized,
critical care areas, hired only experienced nurses. The demand for
nurses in these areas has far exceeded the supply and most insti-
tutions are now faced with the challenge of integrating new nursing
graduates into highly complex work environments. The Duke
Pediatric Blood and Marrow Transplant Unit is no exception. This
type of work environment has been classiﬁed as one of the most
intensive and complex in nursing. The patients are critically ill and
the medical and supportive care needs have been known to over-
whelm even the most experienced nurse. The integration of the
new graduate into this type of environment has created unique
challenges for both experienced staff and nursing leadership. The
purpose of this abstract is to present the Duke Pediatric Blood and
Marrow Transplant “Nursing Graduate Integration Program”.
The program was initiated in 2006 after two consecutive years of
low retention (particularly among new graduates). The new grad-
uates who left the unit described feeling overwhelmed, stressed and
unprepared for the rigorous demands of these patients. Typically
new graduates left the unit for jobs associated with decreased acuity
and less stress. The poster will highlight the key components of our
program including safety, multidisciplinary collaboration and
moral support in attempt to increase quality of care and retention
rates.
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Engraftment syndrome is an important complication causing
early morbidity and nonrelapse mortality in children undergoing
hematopoietic stem cell transplantation. It is used to describe the
symptoms secondary to cytokine release as a reaction to chemo-
therapy and radiation therapy. In some cases, it cannot be distin-
guished from hyperacute graft versus host disease following trans-
plantation. Conditioning regimens prior to transplantation cause
tissue damage which produces release of cytokines. This produc-
tion of cytokines leads to increase in capillary permeability result-
ing in loss of intravascular ﬂuids into the interstitial space. Engraft-
ment syndrome can occur before or along with neutrophil recovery
following cytotoxic chemotherapy. In most cases, fever and eryth-
roderma are the hallmarks of the syndrome. In severe cases, aseptic
shock syndrome with multiple organ failure can occur. Clinical
manifestations of engrafment syndrome include: fever without
identiﬁable infectious etiology, erythematous rash, diarrhea, renal
impairment, ascites, and non-cardiogenic pulmonary edema.
High-dose systemic corticosteriods have been shown to decrease
the duration and lessen the severity of complications related to this
syndrome. Other treatment is supprotive. Nurses play an impor-
tant role in recognizing early manifestations of engraftment syn-
drome by monitoring strict I & O’s, daily weights, respiratory and
hemodynamic status.
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HC is a severe complication associated with HSCT. Condition-
ing regimen, radiotherapy and use of cyclophosphamide are de-
scribed as risk factors; we previously determined that UD HSCT is
independently associated with higher prevalence of HC (El-Zi-
maity et al. Blood 2004).
Developed as a quality improvement project, the main goal of
this prospective study is to evaluate whether BK viruria is a con-
tributing risk factor for development of HC in patients submitted
to UD HSCT. The APN role for this ongoing study is screening
and enrolling eligible patients, and then ordering urine cytology
for polyoma virus and PCR for BK virus in urine before the ﬁrst
day of conditioning regimen. APNs also participate in close fol-
low-up during inpatient period, regarding symptons or signs of
HC, education for interdisciplinary team members, and informing
staff of ongoing results. Anticipated nursing implications include
infusion of platelet concentrates, IVIG, and close monitoring of
urine viral test.
Sixty-two consecutive patients who underwent UD HSCT from
09/05 to 05/06 have completed at least 60 days of follow-up post
HSCT. Results with median follow-up of 97 days include: BK
PCR was positive in 28 patients (45%) previously to transplant; 11
patients (18%) developed HC, at a median of 25 days after HSCT.
In the PCR positive group, 7 patients (25%) had HC, versus 4
(12%) in the PCR-negative group (hazard ratio 3.4 for a positive
PCR; log-rank p  0.057). 100-day cumulative incidence of HC is
30% for PCR-positive and 15% for PCR-negative patients (not a
statistically signiﬁcant result).
Conclusion: the role of BK viruria in this setting is unclear. This
quality improvement project is an example of the importance of a
multidisciplinary taskforce and the APN role in the development of
clinical prospective studies in HSCT.
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